Journal Article
. 2020 Aug;10().
doi: 10.3389/fonc.2020.01315.

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients

Yujie Lu 1 Yiwei Tong 1 Jiahui Huang 1 Lin Lin 2 Jiayi Wu 1 Xiaochun Fei 3 Ou Huang 1 Jianrong He 1 Li Zhu 1 Weiguo Chen 1 Yafen Li 1 Xiaosong Chen 1 Kunwei Shen 1 
Affiliations
  • PMID: 32850415
  •     44 References

Abstract

Background: The 21-gene recurrence score (RS) assay has been proven prognostic and predictive for hormone receptor-positive/HER2-negative, node-negative early breast cancer patients. However, whether primary 21-gene RS can predict prognosis in recurrent breast cancer patients remained unknown. Patients and Methods: Consecutive breast cancer patients operated in Comprehensive Breast Health Center, Shanghai Ruijin Hospital between January 2009 and December 2018 were retrospectively analyzed. Patients with available 21-gene RS result for the primary tumor and reporting disease recurrence during follow-up were included. Association of 21-gene RS and overall survival (OS), post-recurrence overall survival (PR-OS), post-recurrence progression-free survival (PR-PFS), and first-line systemic treatment after recurrence were compared among different groups. Results: A total of 74 recurrent patients were included, with 10, 27, 37 patients in the RS <18, 18-30, and ≥ 31 groups, respectively. Recurrent patients with RS ≥ 31 were more likely to receive chemotherapy as their first-line treatment compared to those with RS <31 (P = 0.025). Compared to those with RS <31, patients with RS ≥ 31 had significantly worse OS (P = 0.025), worse PR-OS (P = 0.026), and a trend of inferior PR-PFS (P = 0.106). Multivariate analysis demonstrated that primary ER expression level (OS: P = 0.009; PR-OS: P = 0.017) and histological grade (OS: P = 0.003; PR-OS: P = 0.009), but not primary 21-gene RS (OS: P = 0.706; PR-OS: P = 0.120), were independently associated with worse OS and PR-OS. Conclusions: High primary 21-gene RS tended to be associated with worse disease outcome in loco-regional and distant recurrent breast cancer patients, which could influence the first-line systemic treatment after relapse, warranting further clinical evaluation.

Keywords: 21-gene RS; breast cancer; first-line treatment; prognosis; recurrence.

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
Jiayi Wu, Yan Fang, +11 authors, Kunwei Shen.
Oncotarget, 2017 Apr 14; 8(24). PMID: 28404972    Free PMC article.
The association between expressions of Ras and CD68 in the angiogenesis of breast cancers.
Wei Li, Rong-Rui Liang, +10 authors, Min Tao.
Cancer Cell Int, 2015 Feb 17; 15(1). PMID: 25685069    Free PMC article.
Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer.
Clodoaldo Zago Campos, Roberta Losi Guembarovski, +6 authors, Tânia Longo Mazzuco.
Clin Exp Med, 2017 Apr 30; 18(1). PMID: 28455582
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
Tari A King, Jaclyn P Lyman, +17 authors, Clifford A Hudis.
J Clin Oncol, 2016 Mar 24; 34(20). PMID: 27001590    Free PMC article.
Prognostic factors in 1,038 women with metastatic breast cancer.
R Largillier, J-M Ferrero, +12 authors, E Chamorey.
Ann Oncol, 2008 Jul 22; 19(12). PMID: 18641006    Free PMC article.
21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Sci Rep, 2019 Sep 13; 9(1). PMID: 31511599    Free PMC article.
ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer.
Cletus A Arciero, Yi Guo, +4 authors, Xiaoxian Li.
Clin Breast Cancer, 2019 Mar 09; 19(4). PMID: 30846407
Metastasis-Free Interval Is Closely Related to Tumor Characteristics and Has Prognostic Value in Breast Cancer Patients with Distant Relapse.
Hee Jun Kim, Sung Gwe Ahn, +4 authors, Joon Jeong.
J Breast Cancer, 2016 Jan 16; 18(4). PMID: 26770244    Free PMC article.
[Analysis of the factors influencing adjuvant chemotherapy decisions for triple negative breast cancer].
J Hong, X S Chen, +7 authors, K W Shen.
Zhonghua Zhong Liu Za Zhi, 2017 Jan 21; 39(1). PMID: 28104032
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis.
Antonio Di Meglio, Rachel A Freedman, +8 authors, Ines Vaz-Luis.
Breast Cancer Res Treat, 2016 Jun 09; 157(3). PMID: 27271765
Predictors of time to death after distant recurrence in breast cancer patients.
Victoria Sopik, Ping Sun, Steven A Narod.
Breast Cancer Res Treat, 2018 Oct 18; 173(2). PMID: 30328050
The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence.
Sung Gwe Ahn, Hak Min Lee, +5 authors, Hy-De Lee.
PLoS One, 2013 May 30; 8(5). PMID: 23717438    Free PMC article.
CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers.
Vasiliki Pelekanou, Franz Villarroel-Espindola, +2 authors, David L Rimm.
Breast Cancer Res, 2018 Dec 19; 20(1). PMID: 30558648    Free PMC article.
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Juhi Asad, Allyson F Jacobson, +7 authors, Paul I Tartter.
Am J Surg, 2008 Sep 24; 196(4). PMID: 18809056
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2020 Jan 09; 70(1). PMID: 31912902
Highly Cited.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
Nicholas P Tobin, Linda S Lindström, +3 authors, Kristian Wennmalm.
Mol Oncol, 2014 Mar 19; 8(3). PMID: 24630985    Free PMC article.
Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer.
Shuang Li, Guan-Tian Lang, +3 authors, Qiang Zhang.
Cancer Med, 2018 Jul 23; 7(9). PMID: 30032483    Free PMC article.
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years.
Amye J Tevaarwerk, Robert J Gray, +7 authors, Joseph A Sparano.
Cancer, 2012 Oct 16; 119(6). PMID: 23065954    Free PMC article.
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
Recurrence in early breast cancer: Analysis of data from 3,765 Australian women treated between 1997 and 2015.
Robin Stuart-Harris, Jane E Dahlstrom, +3 authors, Bruce Shadbolt.
Breast, 2019 Feb 21; 44. PMID: 30785024
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.
Melody A Cobleigh, Bita Tabesh, +7 authors, Steven Shak.
Clin Cancer Res, 2005 Dec 20; 11(24 Pt 1). PMID: 16361546
Identifying the potential long-term survivors among breast cancer patients with distant metastasis.
E S Lee, S Y Jung, +10 authors, H G Moon.
Ann Oncol, 2016 Jan 30; 27(5). PMID: 26823524
Time to death in breast cancer patients as an indicator of treatment response.
Steven A Narod, Vasily Giannakeas, Victoria Sopik.
Breast Cancer Res Treat, 2018 Sep 01; 172(3). PMID: 30168014    Free PMC article.
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Y Delpech, Y Wu, +9 authors, L Pusztai.
Breast Cancer Res Treat, 2012 Aug 15; 135(2). PMID: 22890751
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.
Eitan Amir, Naomi Miller, +9 authors, Mark Clemons.
J Clin Oncol, 2011 Nov 30; 30(6). PMID: 22124102    Free PMC article.
Highly Cited.
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model.
Zhenchong Xiong, Guangzheng Deng, +5 authors, Xi Wang.
Cancer Res Treat, 2018 Jan 16; 50(4). PMID: 29334609    Free PMC article.
Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample.
Siji Zhu, Jiayi Wu, +7 authors, Kunwei Shen.
Ann Surg Oncol, 2019 May 31; 26(9). PMID: 31144143    Free PMC article.
Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer-A Single Institution Experience.
Bianca Rogoz, Agathe Houzé de l'Aulnoit, Alain Duhamel, Denis Houzé de l'Aulnoit.
Clin Breast Cancer, 2017 Oct 11; 18(3). PMID: 28988656
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).
Alastair M Thompson, Lee B Jordan, +5 authors, Breast Recurrence in Tissues Study Group.
Breast Cancer Res, 2010 Nov 10; 12(6). PMID: 21059212    Free PMC article.
Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
D B Geffen.
Ann Oncol, 2018 Apr 11; 29(5). PMID: 29635411
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
F Cardoso, E Senkus, +39 authors, E P Winer.
Ann Oncol, 2018 Jul 23; 29(8). PMID: 30032243    Free PMC article.
Highly Cited.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
A Goldhirsch, J N Ingle, +4 authors, Panel members.
Ann Oncol, 2009 Jun 19; 20(8). PMID: 19535820    Free PMC article.
Highly Cited.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, +3 authors, Ahmedin Jemal.
CA Cancer J Clin, 2018 Sep 13; 68(6). PMID: 30207593
Highly Cited.
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Edith A Perez, Edward H Romond, +7 authors, Norman Wolmark.
J Clin Oncol, 2011 Jul 20; 29(25). PMID: 21768458    Free PMC article.
Highly Cited.
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.
Claudette Falato, Nicholas P Tobin, +3 authors, Theodoros Foukakis.
Mol Oncol, 2015 Dec 15; 10(4). PMID: 26651914    Free PMC article.
Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis.
Xishan Hao, Baocun Sun, +11 authors, Wei Zhang.
Cancer, 2004 Mar 17; 100(6). PMID: 15022276
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.
Theodoros Foukakis, Tommy Fornander, +3 authors, Jonas Bergh.
Breast Cancer Res Treat, 2011 May 28; 130(2). PMID: 21617918
High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers.
Marc A Bollet, Nicolas Servant, +11 authors, Jean-Paul Thiery.
J Natl Cancer Inst, 2007 Dec 27; 100(1). PMID: 18159071
Molecular Concordance Between Primary Breast Cancer and Matched Metastases.
Anne Bruun Krøigård, Martin Jakob Larsen, Mads Thomassen, Torben A Kruse.
Breast J, 2016 Apr 19; 22(4). PMID: 27089067
Review.
Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test.
Susan K Boolbol, Manju Harshan, +8 authors, Stephen Malamud.
Breast Cancer Res Treat, 2019 Jul 16; 177(3). PMID: 31302854    Free PMC article.